Anika Therapeutics, Inc.
ANIK
$9.76
-$0.12-1.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.55% | 16.51% | 4.61% | -0.73% | -47.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.55% | 16.51% | 4.61% | -0.73% | -47.09% |
| Cost of Revenue | 131.82% | 76.62% | 37.77% | 15.44% | -64.39% |
| Gross Profit | -3.54% | -6.69% | -8.94% | -8.02% | -36.75% |
| SG&A Expenses | 68.73% | 25.23% | 11.23% | -7.29% | -70.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.51% | 45.19% | 23.02% | 4.36% | -65.67% |
| Operating Income | -158.10% | -164.22% | -153.91% | -382.41% | 169.51% |
| Income Before Tax | -144.64% | -149.44% | -135.61% | -187.61% | 178.82% |
| Income Tax Expenses | -66.38% | -45.12% | -26.42% | -8.07% | 419.62% |
| Earnings from Continuing Operations | -244.31% | -350.94% | -318.57% | -156.70% | 140.23% |
| Earnings from Discontinued Operations | 33.38% | -45,319.05% | -1,694.92% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.12% | 18.27% | 26.14% | 31.79% | -296.83% |
| EBIT | -158.10% | -164.22% | -153.91% | -382.41% | 169.51% |
| EBITDA | -119.01% | -114.03% | -101.25% | -87.69% | 288.76% |
| EPS Basic | 65.67% | 18.14% | 26.12% | 31.95% | -295.72% |
| Normalized Basic EPS | -142.85% | -144.38% | -129.96% | -154.85% | 182.65% |
| EPS Diluted | 65.52% | 17.95% | 26.12% | 32.04% | -293.00% |
| Normalized Diluted EPS | -142.66% | -144.11% | -129.96% | -154.85% | 182.65% |
| Average Basic Shares Outstanding | -2.21% | -1.40% | -0.33% | 0.43% | 0.59% |
| Average Diluted Shares Outstanding | -1.90% | -1.09% | -0.23% | 0.53% | 0.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |